A detailed history of Ally Bridge Group (Ny) LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Ally Bridge Group (Ny) LLC holds 317,833 shares of ETNB stock, worth $3.48 Million. This represents 2.77% of its overall portfolio holdings.

Number of Shares
317,833
Holding current value
$3.48 Million
% of portfolio
2.77%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$7.03 - $10.05 $2.23 Million - $3.19 Million
317,833 New
317,833 $2.44 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $509M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Ally Bridge Group (Ny) LLC Portfolio

Follow Ally Bridge Group (Ny) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.